AI Article Synopsis
- * While there is evidence linking triglycerides to cardiovascular risk, therapies aimed at lowering triglycerides, like omega-3 fatty acids, have produced mixed results in outcomes.
- * Icosapent ethyl, a specific form of omega-3, has shown promising evidence in reducing cardiovascular risk in patients with high triglyceride levels who are also on statin therapy.
Article Abstract
Low-density lipoprotein cholesterol (LDL-C) is the main target for therapeutics aimed at reducing the risk of atherosclerotic cardiovascular disease (ASCVD) and downstream cardiovascular (CV) events. However, multiple studies have demonstrated that high-risk patient populations harbour residual risk despite effective LDL-C lowering. While data support the causal relationship between triglycerides and ASCVD risk, triglyceride-lowering therapies such as omega-3 fatty acids have shown mixed results in CV outcomes trials. Notably, icosapent ethyl, a purified formulation of eicosapentaenoic acid (EPA), has garnered compelling evidence in lowering residual CV risk in patients with hypertriglyceridaemia and treated with statins. In this review, we summarize studies that have investigated omega-3-fatty acids for CV event lowering and discuss the clinical implementation of these agents based on trial data and guidelines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurjpc/zwae003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!